Senate Bill S5043A

2011-2012 Legislative Session

Establishes a Medicaid drug rebate remittance demonstration program to validate existing Medicaid drug rebate claims

download bill text pdf

Archive: Last Bill Status - In Senate Committee Health Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

Date of Action	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Jan 04, 2012	referred to health returned to senate died in assembly
Jun 21, 2011	referred to health delivered to assembly passed senate
Jun 07, 2011	advanced to third reading
Jun 06, 2011	2nd report cal.
Jun 02, 2011	1st report cal.974
May 10, 2011	print number 5043a
May 10, 2011	amend and recommit to health
May 03, 2011	referred to health

Votes

- Jun 21, 2011 - Floor Vote
  S5043A
  
  Aye
  
  52
  
  Nay
  
  9
  
  Absent
  
  1
  
  Excused
  
  0
  
  Abstained
  
  0
  - - Floor Vote: Jun 21, 2011
      
      aye (52)
      
      Adams
      
      Addabbo Jr.
      
      Alesi
      
      Ball
      
      Bonacic
      
      Breslin
      
      Carlucci
      
      DeFrancisco
      
      Diaz
      
      Dilan
      
      Duane
      
      Farley
      
      Flanagan
      
      Fuschillo
      
      Gallivan
      
      Gianaris
      
      Golden
      
      Griffo
      
      Grisanti
      
      Hannon
      
      Huntley
      
      Johnson
      
      Klein
      
      Kruger
      
      LaValle
      
      Lanza
      
      Larkin
      
      Libous
      
      Little
      
      Marcellino
      
      Martins
      
      Maziarz
      
      McDonald
      
      Nozzolio
      
      O'Mara
      
      Oppenheimer
      
      Ranzenhofer
      
      Ritchie
      
      Rivera
      
      Robach
      
      Saland
      
      Sampson
      
      Savino
      
      Serrano
      
      Seward
      
      Skelos
      
      Squadron
      
      Stavisky
      
      Stewart-Cousins
      
      Valesky
      
      Young
      
      Zeldin
      
      nay (9)
      
      Avella
      
      Espaillat
      
      Hassell-Thompson
      
      Kennedy
      
      Krueger
      
      Montgomery
      
      Parker
      
      Peralta
      
      Perkins
      
      absent (1)
      
      Smith
  Jun 2, 2011 - Health Committee Vote
  S5043A
  
  Aye
  
  11
  
  Nay
  
  0
  
  Aye with Reservations
  
  2
  
  Absent
  
  0
  
  Excused
  
  4
  
  Abstained
  
  0
  - - Health Committee Vote: Jun 2, 2011
      
      aye (11)
      
      Ball
      
      Farley
      
      Fuschillo
      
      Golden
      
      Hannon
      
      Larkin
      
      McDonald
      
      Montgomery
      
      Seward
      
      Stewart-Cousins
      
      Young
      
      aye wr (2)
      
      Gianaris
      
      Rivera
      
      excused (4)
      
      Adams
      
      Duane
      
      Kruger
      
      Smith

Bill Amendments

2011-S5043 - Details

Current Committee:: Senate Health
Law Section:: Public Health Law
Laws Affected:: Add §276-b, Pub Health L

2011-S5043 - Summary

Establishes a Medicaid drug rebate remittance demonstration program to authorize the department of health to work collaboratively with third party vendors to validate existing Medicaid drug rebate claims and the data contains duplicate claims or claims on which rebates may have already been paid all or in part to Medicare Part D plans or some other third parties in order to rectify disputed claims.

2011-S5043 - Sponsor Memo

                                BILL NUMBER:S5043

TITLE OF BILL:
An act
to amend the public health law, in relation to establishing a medicaid
drug rebate remittance demonstration program

PURPOSE OR GENERAL IDEA OF BILL: This bill will
establish a Medicaid drug rebate remittance demonstration program within
the Department of Health for the purpose of working collaboratively with
the pharmaceutical industry and third party vendors to validate drug
rebate claims and rectify disputed claims.

SUMMARY OF SPECIFIC PROVISIONS: This bill adds a new
section 276-b to the Public Health Law.

Subdivision 1 establishes the Medicaid drug rebate remittance
demonstration program to work collaboratively with third party vendors
to validate existing Medicaid drug rebate claims to determine whether
the data contains duplicate claims or claims on which rebates may
already have been paid all or in part to Medicare Part D plans or some
other third parties in order to rectify disputed claims.

Subdivision 2 sets forth the parameters of the demonstration program and
the information required to be shared with drug manufacturers and third
party vendors. It states that the Department of Health shall provide

prescription drug utilization information to participating drug
manufacturers who have entered into a rebate agreement with the
Department and third party data vendors at no cost to the Department.

Subdivision 3 sets forth reporting requirements and recommendation
options by the Department of Health. The Department shall report on the
results of the program to the Governor, the Director of the Division of
the Budget, the state Comptroller, and the Legislature on or before
December 31, 2012.

JUSTIFICATION: In August 2004, the U.S. Department of
Health & Human Services (HHS) Office of Inspector General released an
audit of New York's Medicaid Drug Rebate Program billings, collections
and dispute resolutions. HHS determined that "the processes and controls
for rebate billings, collections, and dispute resolutions were not
always coordinated effectively, did not maximize savings and did not
produce accurate and complete records of rebate activities." Among its
findings, HHS identified an estimated balance of $351 million in total
outstanding rebates, including $32 million in unresolved disputes, as of
June 30,2002.

Medicaid programs in over 45 states boost their Medicaid drug rebate
collections by disclosing prescription-level data to third party vendors
with expertise in providing standardized databases to validate Medicaid
rebate invoices and expedite the resolution of disputed claims, in an
unbiased, objective manner. According to the Centers for Medicare and
Medicaid Services (CMS), "data vendors can be invaluable for the purpose
of validation drug rebate data, identifying potential errors and
achieving dispute resolution between States and pharmaceutical
manufacturers." The California Department of Health Services noted that
since providing claims detail data to a third party data vendor, "the


percentage paid of the invoiced amount has increased" and "companies pay
a larger amount within the initial payment timeframe."

This bill will require NYSDOH to share information and work
cooperatively with third party data vendors in a demonstration program
to determine the extent to which such collaboration will maximize
Medicaid drug rebate revenues to the State.

PRIOR LEGISLATIVE HISTORY: Similar to S.5835/A.8869
of 2005. Vetoed.

FISCAL IMPLICATIONS: No cost to the State. Potential
increase in revenues based upon resolution of disputed rebate amounts.

EFFECTIVE DATE: Immediately upon enactment.

2011-S5043 - Bill Text download pdf

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  5043

                       2011-2012 Regular Sessions

                            I N  S E N A T E

                               May 3, 2011
                               ___________

Introduced  by  Sen.  HANNON -- read twice and ordered printed, and when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law, in  relation  to  establishing  a
  medicaid drug rebate remittance demonstration program

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. The public health law is amended by adding  a  new  section
276-b to read as follows:
  S  276-B.  MEDICAID  DRUG REBATE REMITTANCE DEMONSTRATION PROGRAM.  1.
THE DEPARTMENT SHALL ESTABLISH A MEDICAID DRUG REBATE REMITTANCE  DEMON-
STRATION  PROGRAM  FOR THE PURPOSE OF WORKING COLLABORATIVELY WITH THIRD
PARTY VENDORS TO VALIDATE THE EXISTING MEDICAID DRUG REBATE  CLAIMS  AND
DETERMINE  WHETHER THE DATA CONTAINS DUPLICATE CLAIMS OR CLAIMS ON WHICH
REBATES MAY ALREADY HAVE BEEN PAID ALL OR IN PART  TO  MEDICARE  PART  D
PLANS OR SOME OTHER THIRD PARTIES IN ORDER TO RECTIFY DISPUTED CLAIMS.
  2.  FOR  THE  PURPOSES  OF  THIS DEMONSTRATION PROGRAM, THE DEPARTMENT
SHALL PROVIDE UTILIZATION INFORMATION TYING TO INVOICES SENT TO  PHARMA-
CEUTICAL  MANUFACTURERS, WHICH HAVE ENTERED INTO A REBATE AGREEMENT WITH
THE DEPARTMENT OR  WITH  THE  FEDERAL  SECRETARY  OF  HEALTH  AND  HUMAN
SERVICES  ON  BEHALF OF THE DEPARTMENT UNDER SECTION 1927 OF THE FEDERAL
SOCIAL SECURITY ACT, AND TO THIRD PARTY DATA VENDORS, FOR THE PURPOSE OF
VALIDATING CLAIMS SUBMITTED  UNDER  SUCH  REBATE  AGREEMENT  OR  PROGRAM
INCLUDING  BUT  NOT  LIMITED  TO, THE PROGRAM FOR ELDERLY PHARMACEUTICAL
INSURANCE COVERAGE, AND THE MEDICAID DRUG REBATE PROGRAM IN GENERAL  FOR
THE PERIOD FROM JANUARY FIRST, TWO THOUSAND NINE THROUGH JUNE THIRTIETH,
TWO THOUSAND TWELVE. SUCH UTILIZATION INFORMATION SHALL INCLUDE, BUT NOT
BE  LIMITED  TO:  PRESCRIPTION  NUMBERS,  NATIONAL DRUG CODES, NUMBER OF
UNITS DISPENSED, CLAIMS PAID DATE, DATE OF SERVICE,  PRESCRIBING  PHYSI-
CIAN  STATE  IDENTIFICATION NUMBER, AMOUNT BILLED FOR EACH PRESCRIPTION,
AMOUNT OF REIMBURSEMENT RECEIVED FOR EACH  PRESCRIPTION  (INCLUDING  ANY
ADJUSTMENT  CODES),  DISPENSING  PHARMACY'S STATE IDENTIFICATION NUMBER,

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD11186-01-1

S. 5043                             2

DISPENSING FEE, ANY APPLICABLE THIRD-PARTY PAYMENTS, APPLICABLE  CO-PAY-
MENTS,  REFILL  CODE,  INTERNAL CLAIM NUMBER OF THE SCRIPT, DAYS SUPPLY,
J-CODE CLAIMS INCLUDING SINGLE SOURCE AND MULTISOURCE PHYSICIAN ADMINIS-
TERED  DRUGS,  NPI  NUMBERS, MCO PLAN IDENTIFIER, MCO PLAN NAME, AND THE
NAME, ADDRESS, CITY, STATE AND ZIP CODE OF THE PRESCRIBING  PRACTITIONER
AND  PHARMACY.  THE  PRESCRIPTION  DRUG UTILIZATION INFORMATION SHALL BE
PROVIDED TO THE THIRD PARTY DATA VENDORS AS SOON AS PRACTICABLE  FOLLOW-
ING ESTABLISHMENT OF THIS PROGRAM. THERE SHALL BE NO COST TO THE DEPART-
MENT   FOR   SERVICES   PERFORMED  BY  THIRD  PARTY  DATA  VENDORS.  ANY
PRESCRIPTION DRUG UTILIZATION DATA PROVIDED TO THIRD PARTY DATA  VENDORS
UNDER THIS DEMONSTRATION PROGRAM SHALL NOT BE SHARED WITH OTHER PARTIES,
EXCEPT  PARTICIPATING  DRUG MANUFACTURERS WHO HAVE ENTERED INTO A REBATE
AGREEMENT WITH THE DEPARTMENT OR WITH THE FEDERAL  SECRETARY  OF  HEALTH
AND HUMAN SERVICES ON BEHALF OF THE DEPARTMENT UNDER SECTION 1927 OF THE
FEDERAL  SOCIAL  SECURITY  ACT.  UTILIZATION  DATA  PROVIDED  UNDER THIS
SECTION SHALL BE USED  FOR  THE  FOLLOWING  PURPOSE:  REBATE  VALIDATION
SERVICES  FOR  THE  BENEFIT OF DRUG COMPANIES AND STATE/FEDERAL AGENCIES
INCLUDING DRUG USE TREND REVIEW. INDIVIDUAL PATIENT IDENTIFYING INFORMA-
TION SHALL BE KEPT CONFIDENTIAL BY ANY PERSON OR ENTITY TO  WHOM  OR  TO
WHICH IT IS PROVIDED UNDER THIS SECTION. THE DISCLOSURE OF THE FOREGOING
DATA  BY  THE  DEPARTMENT  SHALL  BE CONSIDERED, FOR PURPOSES OF SECTION
THREE HUNDRED SIXTY-NINE OF THE SOCIAL  SERVICES  LAW,  TO  BE  DIRECTLY
CONNECTED  WITH  THE  ADMINISTRATION  OF  MEDICAL  ASSISTANCE  FOR NEEDY
PERSONS.
  3. THE DEPARTMENT SHALL PROVIDE A REPORT ON THE RESULTS OF THE  DEMON-
STRATION  PROGRAM TO THE GOVERNOR, THE DIRECTOR OF THE DIVISION OF BUDG-
ET, THE STATE COMPTROLLER AND THE  LEGISLATURE  ON  OR  BEFORE  DECEMBER
THIRTY-FIRST,  TWO THOUSAND TWELVE. THE REPORT SHALL INCLUDE FINDINGS AS
TO THE DEMONSTRATION PROGRAM'S CONTRIBUTION TO IMPROVING THE ABILITY  OF
THE  DEPARTMENT  TO  VALIDATE  DRUG  REBATE  CLAIMS AND RECTIFY DISPUTED
CLAIMS. IN THE REPORT, THE DEPARTMENT SHALL OFFER RECOMMENDATIONS AS  TO
WHETHER  THE  DEMONSTRATION PROGRAM SHOULD BE EXTENDED, MODIFIED, ELIMI-
NATED OR MADE PERMANENT.
  S 2. This act shall take effect immediately, provided,  however,  that
the  amendments  to article 2-A of the public health law made by section
one of this act shall survive the repeal of such article as provided  in
section 79 of part C of chapter 58 of the laws of 2005, as amended.

2011-S5043A (ACTIVE) - Details

Current Committee:: Senate Health
Law Section:: Public Health Law
Laws Affected:: Add §276-b, Pub Health L

2011-S5043A (ACTIVE) - Summary

2011-S5043A (ACTIVE) - Sponsor Memo

                                BILL NUMBER:S5043A

TITLE OF BILL:
An act
to amend the public health law, in relation to establishing a medicaid
drug rebate remittance demonstration program

PURPOSE OR GENERAL IDEA OF BILL:
This bill will
establish a Medicaid drug rebate remittance demonstration program within
the Department of Health for the purpose of working collaboratively with
the pharmaceutical industry and third party vendors to validate drug
rebate claims and rectify disputed claims.

SUMMARY OF SPECIFIC PROVISIONS:
This bill adds a new section 276-b to the Public Health Law.

Subdivision 1 establishes the Medicaid drug rebate remittance
demonstration program to work collaboratively with third party vendors
to validate existing Medicaid drug rebate claims to determine whether
the data contains duplicate claims or claims on which rebates may
already have been paid all or in part to Medicare Part D plans or some
other third parties in order to rectify disputed claims.

Subdivision 2 sets forth the parameters of the demonstration program and
the information required to be shared with drug manufacturers and third

party vendors. It states that the Department of Health shall provide
prescription drug utilization information to participating drug
manufacturers who have entered into a rebate agreement with the
Department and third party data vendors at no cost to the Department.

Subdivision 3 sets forth reporting requirements and recommendation
options by the Department of Health. The Department shall report on the
results of the program to the Governor, the Director of the Division of
the Budget, the state Comptroller, and the Legislature on or before
December 31, 2012.

JUSTIFICATION:
In August 2004, the U.S. Department of
Health & Human Services (HHS) Office of Inspector General released an
audit of New York's Medicaid Drug Rebate Program billings, collections
and dispute resolutions. HHS determined that "the processes and controls
for rebate billings, collections, and dispute resolutions were not
always coordinated effectively, did not maximize savings and did not
produce accurate and complete records of rebate activities." Among its
findings, HHS identified an estimated balance of $351 million in total
outstanding rebates, including $32 million in unresolved disputes, as of
June 30, 2002.

Medicaid programs in over 45 states boost their Medicaid drug rebate
collections by disclosing prescription-level data to third party vendors
with expertise in providing standardized databases to validate Medicaid
rebate invoices and expedite the resolution of disputed claims, in an
unbiased, objective manner. According to the Centers for Medicare and
Medicaid Services (CMS), "data vendors can be invaluable for the purpose
of validation drug rebate data, identifying potential errors and


achieving dispute resolution between States and pharmaceutical
manufacturers." The California Department of Health Services noted that
since providing claims detail data to a third party data vendor, "the
percentage paid of the invoiced amount has increased" and "companies pay
a larger amount within the initial payment timeframe."

This bill will require NYSDOH to share information and work
cooperatively with third party data vendors in a demonstration program
to determine the extent to which such collaboration will maximize
Medicaid drug rebate revenues to the State.

PRIOR LEGISLATIVE HISTORY:
Similar to S.5835/A.8869 of 2005. Vetoed.

FISCAL IMPLICATIONS:
No cost to the State. Potential
increase in revenues based upon resolution of disputed rebate amounts.

EFFECTIVE DATE:
Immediately upon enactment.

2011-S5043A (ACTIVE) - Bill Text download pdf

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 5043--A

                       2011-2012 Regular Sessions

                            I N  S E N A T E

                               May 3, 2011
                               ___________

Introduced  by  Sen.  HANNON -- read twice and ordered printed, and when
  printed to be committed  to  the  Committee  on  Health  --  committee
  discharged, bill amended, ordered reprinted as amended and recommitted
  to said committee

AN  ACT  to  amend  the public health law, in relation to establishing a
  medicaid drug rebate remittance demonstration program

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  The  public health law is amended by adding a new section
276-b to read as follows:
  S 276-B. MEDICAID DRUG REBATE REMITTANCE DEMONSTRATION  PROGRAM.    1.
THE  DEPARTMENT SHALL ESTABLISH A MEDICAID DRUG REBATE REMITTANCE DEMON-
STRATION PROGRAM FOR THE PURPOSE OF WORKING COLLABORATIVELY  WITH  THIRD
PARTY  VENDORS  TO VALIDATE THE EXISTING MEDICAID DRUG REBATE CLAIMS AND
DETERMINE WHETHER THE DATA CONTAINS DUPLICATE CLAIMS OR CLAIMS ON  WHICH
REBATES  MAY  ALREADY  HAVE  BEEN PAID ALL OR IN PART TO MEDICARE PART D
PLANS OR SOME OTHER THIRD PARTIES IN ORDER TO RECTIFY DISPUTED CLAIMS.
  2. FOR THE PURPOSES OF  THIS  DEMONSTRATION  PROGRAM,  THE  DEPARTMENT
SHALL  PROVIDE UTILIZATION INFORMATION TYING TO INVOICES SENT TO PHARMA-
CEUTICAL MANUFACTURERS, WHICH HAVE ENTERED INTO A REBATE AGREEMENT  WITH
THE  DEPARTMENT  OR  WITH  THE  FEDERAL  SECRETARY  OF  HEALTH AND HUMAN
SERVICES ON BEHALF OF THE DEPARTMENT UNDER SECTION 1927 OF  THE  FEDERAL
SOCIAL SECURITY ACT, AND TO THIRD PARTY DATA VENDORS, FOR THE PURPOSE OF
VALIDATING  CLAIMS  SUBMITTED  UNDER  SUCH  REBATE  AGREEMENT OR PROGRAM
INCLUDING BUT NOT LIMITED TO, THE  PROGRAM  FOR  ELDERLY  PHARMACEUTICAL
INSURANCE  COVERAGE, AND THE MEDICAID DRUG REBATE PROGRAM IN GENERAL FOR
THE PERIOD FROM JANUARY FIRST, TWO THOUSAND NINE THROUGH JUNE THIRTIETH,
TWO THOUSAND TWELVE. SUCH UTILIZATION INFORMATION SHALL INCLUDE, BUT NOT
BE LIMITED TO: PRESCRIPTION NUMBERS,  NATIONAL  DRUG  CODES,  NUMBER  OF
UNITS  DISPENSED,  CLAIMS PAID DATE, DATE OF SERVICE, PRESCRIBING PHYSI-
CIAN STATE IDENTIFICATION NUMBER, AMOUNT BILLED FOR  EACH  PRESCRIPTION,

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD11186-02-1

S. 5043--A                          2

AMOUNT  OF  REIMBURSEMENT  RECEIVED FOR EACH PRESCRIPTION (INCLUDING ANY
ADJUSTMENT CODES), DISPENSING PHARMACY'S  STATE  IDENTIFICATION  NUMBER,
DISPENSING  FEE, ANY APPLICABLE THIRD-PARTY PAYMENTS, APPLICABLE CO-PAY-
MENTS,  REFILL  CODE,  INTERNAL CLAIM NUMBER OF THE SCRIPT, DAYS SUPPLY,
J-CODE CLAIMS INCLUDING SINGLE SOURCE AND MULTISOURCE PHYSICIAN ADMINIS-
TERED DRUGS, NPI NUMBERS, MCO PLAN IDENTIFIER, MCO PLAN  NAME,  AND  THE
NAME,  ADDRESS, CITY, STATE AND ZIP CODE OF THE PRESCRIBING PRACTITIONER
AND PHARMACY. THE PRESCRIPTION DRUG  UTILIZATION  INFORMATION  SHALL  BE
PROVIDED  TO THE THIRD PARTY DATA VENDORS AS SOON AS PRACTICABLE FOLLOW-
ING ESTABLISHMENT OF THIS PROGRAM. THERE SHALL BE NO COST TO THE DEPART-
MENT  FOR  SERVICES  PERFORMED  BY  THIRD  PARTY   DATA   VENDORS.   ANY
PRESCRIPTION  DRUG UTILIZATION DATA PROVIDED TO THIRD PARTY DATA VENDORS
UNDER THIS DEMONSTRATION PROGRAM SHALL NOT BE SHARED WITH OTHER PARTIES,
EXCEPT PARTICIPATING DRUG MANUFACTURERS WHO HAVE ENTERED INTO  A  REBATE
AGREEMENT  WITH  THE  DEPARTMENT OR WITH THE FEDERAL SECRETARY OF HEALTH
AND HUMAN SERVICES ON BEHALF OF THE DEPARTMENT UNDER SECTION 1927 OF THE
FEDERAL SOCIAL  SECURITY  ACT.  UTILIZATION  DATA  PROVIDED  UNDER  THIS
SECTION  SHALL  BE  USED  FOR  THE  FOLLOWING PURPOSE: REBATE VALIDATION
SERVICES FOR THE BENEFIT OF DRUG COMPANIES  AND  STATE/FEDERAL  AGENCIES
INCLUDING DRUG USE TREND REVIEW. INDIVIDUAL PATIENT IDENTIFYING INFORMA-
TION  SHALL  BE  KEPT CONFIDENTIAL BY ANY PERSON OR ENTITY TO WHOM OR TO
WHICH IT IS PROVIDED UNDER THIS SECTION. THE DISCLOSURE OF THE FOREGOING
DATA BY THE DEPARTMENT SHALL BE  CONSIDERED,  FOR  PURPOSES  OF  SECTION
THREE  HUNDRED  SIXTY-NINE  OF  THE  SOCIAL SERVICES LAW, TO BE DIRECTLY
CONNECTED WITH  THE  ADMINISTRATION  OF  MEDICAL  ASSISTANCE  FOR  NEEDY
PERSONS.
  3.  THE DEPARTMENT SHALL PROVIDE A REPORT ON THE RESULTS OF THE DEMON-
STRATION PROGRAM, WITH INPUT FROM STAKEHOLDERS,  TO  THE  GOVERNOR,  THE
DIRECTOR OF THE DIVISION OF BUDGET, THE STATE COMPTROLLER AND THE LEGIS-
LATURE  ON  OR  BEFORE  DECEMBER  THIRTY-FIRST, TWO THOUSAND TWELVE. THE
REPORT SHALL INCLUDE FINDINGS AS TO THE DEMONSTRATION PROGRAM'S CONTRIB-
UTION TO IMPROVING THE ABILITY OF THE DEPARTMENT TO VALIDATE DRUG REBATE
CLAIMS AND RECTIFY DISPUTED CLAIMS. IN THE REPORT, THE DEPARTMENT  SHALL
OFFER  RECOMMENDATIONS AS TO WHETHER THE DEMONSTRATION PROGRAM SHOULD BE
EXTENDED, MODIFIED, ELIMINATED OR MADE PERMANENT.
  S 2. This act shall take effect immediately, provided,  however,  that
the  amendments  to article 2-A of the public health law made by section
one of this act shall survive the repeal of such article as provided  in
section 79 of part C of chapter 58 of the laws of 2005, as amended.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Find your Senator and share your views on important issues.

Do you support this bill?

Senate Bill S5043A

Sponsored By

Archive: Last Bill Status - In Senate Committee Health Committee

Actions

Votes

Jun 21, 2011 - Floor Vote

Floor Vote: Jun 21, 2011

Jun 2, 2011 - Health Committee Vote

Health Committee Vote: Jun 2, 2011

Bill Amendments

2011-S5043 - Details

2011-S5043 - Summary

2011-S5043 - Sponsor Memo

2011-S5043 - Bill Text download pdf

2011-S5043A (ACTIVE) - Details

2011-S5043A (ACTIVE) - Summary

2011-S5043A (ACTIVE) - Sponsor Memo

2011-S5043A (ACTIVE) - Bill Text download pdf

Comments

Do you support this bill?

Get Status Alerts for 2011-S5043A

Senate Bill S5043A

Share this bill

Sponsored By

Kemp Hannon

Archive: Last Bill Status - In Senate Committee Health Committee

Actions

Votes

Bill Amendments

2011-S5043 - Details

2011-S5043 - Summary

2011-S5043 - Sponsor Memo

2011-S5043 - Bill Text download pdf

2011-S5043A (ACTIVE) - Details

2011-S5043A (ACTIVE) - Summary

2011-S5043A (ACTIVE) - Sponsor Memo

2011-S5043A (ACTIVE) - Bill Text download pdf

Comments